Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

Ammar Wakil, Alan S. Rigby, Andrew L. Clark, Anna Kallvikbacka-Bennett, Stephen Atkin

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease. Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database. Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0-9.6 and 0.8-78.4, P=0.04 and P<0.0001 respectively). Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3-4 years is not associated with an increased risk of clinically significant valvular regurgitation.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume159
Issue number4
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

Fingerprint

Heart Valve Diseases
Hyperprolactinemia
Parkinson Disease
Echocardiography
Pulmonary Valve Insufficiency
Tricuspid Valve Insufficiency
Dopamine Agonists
Aortic Valve
Mitral Valve
cabergoline
Color
Odds Ratio
Databases
Confidence Intervals

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. / Wakil, Ammar; Rigby, Alan S.; Clark, Andrew L.; Kallvikbacka-Bennett, Anna; Atkin, Stephen.

In: European Journal of Endocrinology, Vol. 159, No. 4, 10.2008.

Research output: Contribution to journalArticle

Wakil, Ammar ; Rigby, Alan S. ; Clark, Andrew L. ; Kallvikbacka-Bennett, Anna ; Atkin, Stephen. / Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. In: European Journal of Endocrinology. 2008 ; Vol. 159, No. 4.
@article{ec8f62cb60b74fb28b1b47d64827a447,
title = "Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease",
abstract = "Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease. Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database. Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95{\%} confidence interval 1.0-9.6 and 0.8-78.4, P=0.04 and P<0.0001 respectively). Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3-4 years is not associated with an increased risk of clinically significant valvular regurgitation.",
author = "Ammar Wakil and Rigby, {Alan S.} and Clark, {Andrew L.} and Anna Kallvikbacka-Bennett and Stephen Atkin",
year = "2008",
month = "10",
doi = "10.1530/EJE-08-0365",
language = "English",
volume = "159",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "4",

}

TY - JOUR

T1 - Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

AU - Wakil, Ammar

AU - Rigby, Alan S.

AU - Clark, Andrew L.

AU - Kallvikbacka-Bennett, Anna

AU - Atkin, Stephen

PY - 2008/10

Y1 - 2008/10

N2 - Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease. Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database. Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0-9.6 and 0.8-78.4, P=0.04 and P<0.0001 respectively). Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3-4 years is not associated with an increased risk of clinically significant valvular regurgitation.

AB - Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease. Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database. Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0-9.6 and 0.8-78.4, P=0.04 and P<0.0001 respectively). Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3-4 years is not associated with an increased risk of clinically significant valvular regurgitation.

UR - http://www.scopus.com/inward/record.url?scp=54049134742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049134742&partnerID=8YFLogxK

U2 - 10.1530/EJE-08-0365

DO - 10.1530/EJE-08-0365

M3 - Article

VL - 159

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 4

ER -